Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 January 2005, Vol. 105, No. 1, pp. 22-30.
Prepublished online as a Blood First Edition Paper on September 9, 2004; DOI 10.1182/blood-2003-11-3896.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-11-3896v1
105/1/22    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wadleigh, M.
Right arrow Articles by Stone, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wadleigh, M.
Right arrow Articles by Stone, R. M.
Related Collections
Right arrow Neoplasia
Right arrow Oncogenes and Tumor Suppressors
Right arrow Reviews in Translational Hematology
Right arrow Free Research Articles
Right arrow Clinical Trials and Observations
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

REVIEW IN TRANSLATIONAL HEMATOLOGY

After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies

Martha Wadleigh, Daniel J. DeAngelo, James D. Griffin, and Richard M. Stone

From the Leukemia Program, Division of Hematologic Malignancy, Department of Medical Oncology, Dana Farber Cancer Institute; and Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

Tyrosine kinases phosphorylate proteins on tyrosine residues, producing a biologic signal that influences many aspects of cellular function including cell growth, proliferation, differentiation, and death. Constitutive or unregulated activity through mutation or overexpression of these enzymes is a common pathologic feature in many acute and chronic leukemias. Inhibition of tyrosine kinases represents a strategy to disrupt signaling pathways that promote neoplastic growth and survival in hematologic malignancies and likely in other neoplasias as well. This review focuses on tyrosine kinases that have been implicated in the pathogenesis of hematologic diseases other than chronic myelogenous leukemia and discusses the evidence for the use of small molecules to target these kinases.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
T. Trowe, S. Boukouvala, K. Calkins, R. E. Cutler Jr., R. Fong, R. Funke, S. B. Gendreau, Y. D. Kim, N. Miller, J. R. Woolfrey, et al.
EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
Clin. Cancer Res., April 15, 2008; 14(8): 2465 - 2475.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
A. F. Remacha, C. Estivill, M. P. Sarda, J. Mateo, J. C. Souto, C. Canals, J. Nomdedeu, and J. Fontcuberta
The V617F mutation of JAK2 is very uncommon in patients with thrombosis
Haematologica, February 1, 2007; 92(2): 285 - 286.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Knapper, K. I. Mills, A. F. Gilkes, S. J. Austin, V. Walsh, and A. K. Burnett
The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases
Blood, November 15, 2006; 108(10): 3494 - 3503.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Schnittger, T. M. Kohl, T. Haferlach, W. Kern, W. Hiddemann, K. Spiekermann, and C. Schoch
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival
Blood, March 1, 2006; 107(5): 1791 - 1799.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Q. Xu, J. E. Thompson, and M. Carroll
mTOR regulates cell survival after etoposide treatment in primary AML cells
Blood, December 15, 2005; 106(13): 4261 - 4268.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
R. Chen and W. Plunkett
Sequential Blockade of Oncogenic Kinases
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 344 - 348.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
J. D. Licht and D. W. Sternberg
The Molecular Pathology of Acute Myeloid Leukemia
Hematology, January 1, 2005; 2005(1): 137 - 142.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020